Avicanna Inc
AVCN
Company Profile
Business description
Avicanna Inc is a commercial-stage international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for the medical and pharmaceutical market segments. It has three operating segments: Canada, International, and Corporate. It generates the majority of its revenue from Canada.
Contact
480 University Avenue
Suite 1502
TorontoBCM5G 1V2
CANT: +1 647 243-5283
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
37
Stocks News & Analysis
stocks
Avoid these overvalued ASX shares
The two shares with the highest price to fair value in our Australian coverage.
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Watching AI monetization, capex’s impact on margins, and guidance on Azure.
stocks
Lithium’s latest drop and what it means for ASX investors
Volatility returns to the lithium market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,004.90 | 14.70 | 0.16% |
| CAC 40 | 8,442.97 | 79.83 | 0.95% |
| DAX 40 | 25,094.19 | 82.84 | 0.33% |
| Dow JONES (US) | 52,224.64 | 385.38 | 0.74% |
| FTSE 100 | 10,733.82 | 147.91 | 1.40% |
| HKSE | 24,892.66 | 239.63 | -0.95% |
| NASDAQ | 25,837.21 | 329.13 | 1.29% |
| Nikkei 225 | 66,115.60 | 116.59 | -0.18% |
| NZX 50 Index | 13,763.18 | 107.15 | 0.78% |
| S&P 500 | 7,509.20 | 65.92 | 0.89% |
| S&P/ASX 200 | 8,823.00 | 16.50 | 0.19% |
| SSE Composite Index | 3,867.03 | 2.67 | 0.07% |